Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 9/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11910412 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1LMNARAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL354023 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| SCHEMBL30833982 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| SCHEMBL104396 | 0.80 | KEAP1 (0.48) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| SCHEMBL29412881 | 0.80 | KEAP1 (0.48) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| Hydrochloric Acid SCHEMBL6331781 | 0.78 | KEAP1 (0.47) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| SCHEMBL11508892 | 0.78 | ALDH1A1 (0.43) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| SCHEMBL669037 | 0.78 | CASP1 (0.56) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| SCHEMBL30752128 | 0.78 | TDP1 (0.41) | ALDH1A1LMNARAB9AL3MBTL1TDP1 | |
| SCHEMBL30567603 | 0.78 | ALDH1A1 (0.54) | ALDH1A1LMNARAB9AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033454-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| US-20180118942-A1 | REACTIVE LEUCO COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY | 2018-05-03 | — | — | US | disclosed |
| EP-3068777-B1 | 1-(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| EP-3068777-B1 | 1-(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017133665-A1 | 6,7-DIAZAINDAZOLE AND 6,7-DIAZAINDOLE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
| US-9723840-B2 | 1-(pyridazin-3-yl)-imidazolidin-2-one derivatives as herbicides | SYNGENTA LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9723840-B2 | 1-(pyridazin-3-yl)-imidazolidin-2-one derivatives as herbicides | SYNGENTA LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9723840-B2 | 1-(pyridazin-3-yl)-imidazolidin-2-one derivatives as herbicides | SYNGENTA LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| EP-3068777-A1 | 1 -(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | Syngenta Participations AG (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20160262395-A1 | 1-(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-15 | — | — | US | disclosed |
| US-20160262395-A1 | 1-(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-15 | — | — | US | disclosed |
| US-20160262395-A1 | 1-(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-15 | — | — | US | disclosed |
| WO-2015067701-A1 | 1 -(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067701-A1 | 1 -(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-05-14 | — | — | WO | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | ALDH1A1 3128/4885LMNA 3669/4885RAB9A 3030/4885 |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | ALDH1A1 259/4885LMNA 688/4885RAB9A 2666/4885 |
| US-20160262395-A1 | 1-(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES | DDT, CBR3, CBR1 | ALDH1A1 238/4885LMNA 4023/4885RAB9A 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.